[Metabolic syndrome in menopause: physiopathological, clinic and therapeutic aspects for cardiovascular prevention].
The authors consider the main endocrinological modifications that happen during the menopausal period, and underline the related metabolic alterations leading the woman to metabolic syndrome and consequently to increase the cardiovascular risk. The components of this syndrome regard the most recent criteria and the respective therapeutic choises are also considered. Moreover, it is encouraged the creation of specifical multi-disciplinar diagnostic and therapeutic iter to prevent the cardiovascular risk in menopause and to improve the life quality in this part of population.
Sinagra
Domenico
D
Cattedra di Endocrinologia, Dipartimento di Oncologia Sperimentale ed Applicazioni Cliniche, Ambulatorio Patologie endocrino-metaboliche in menopausa, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo. sinagra@unipa.it
Conti
Michela
M
D000328:Adult; D000367:Age Factors; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D015444:Exercise; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D008593:Menopause / Q000502:physiology; D024821:Metabolic Syndrome / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000517:prevention & control; D011788:Quality of Life; D012307:Risk Factors; D012737:Sex Factors; D015431:Weight Loss; D014944:World Health Organization
D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents